GSK Tender Offer for RAPT Therapeutics Clears HSR, Faces Shareholder Lawsuits

summarizeSummary

GSK's tender offer for RAPT Therapeutics has cleared a major regulatory hurdle with the expiration of the HSR Act waiting period, but the acquisition now faces two shareholder lawsuits and multiple demand letters alleging disclosure deficiencies.

check_boxKey Events · M&A and Partnerships · RAPT

• HSR Act Waiting Period Expired

  The waiting period under the HSR Act expired on February 23, 2026, at 11:59 p.m. Eastern Time, satisfying a key regulatory condition for the tender offer.

• Shareholder Lawsuits Filed

  Two complaints were filed in New York state court on February 3 and February 5, 2026, by purported stockholders, alleging negligent misrepresentation and concealment based on statements in the Schedule 14D-9.

• Demand Letters Received

  The company also received twelve demand letters from purported stockholders regarding alleged disclosure deficiencies in the Schedule 14D-9.

auto_awesomeAnalysis · RAPT · Life Sciences

This amendment provides a critical update on the ongoing acquisition of RAPT Therapeutics by GSK. The expiration of the HSR Act waiting period satisfies a key regulatory condition, moving the tender offer closer to completion. However, the disclosure of two new shareholder lawsuits and twelve demand letters introduces new legal risks and potential delays to the transaction. While such lawsuits are common in M&A deals, they can lead to additional costs or minor adjustments to disclosures, though they rarely derail a deal entirely, especially one trading at the offer price.